title: Safety and immunogenicity of a live recombinant canarypox virus expressing HIV type 1 gp120 MN MN tm/gag/protease LAI (ALVAC-HIV, vCP205) followed by a p24E-V3 MN synthetic peptide (CLTB-36) administered in healthy volunteers at low risk for HIV infection. AGIS Group and L'Agence Nationale de Recherches sur Le Sida.
abstract: A live recombinant canarypox vector expressing HIV-1 gpl20 MN tm/gag/protease LAI (ALVAC-HIV, vCP205) alone or boosted by a p24E-V3 MN synthetic peptide (CLTB-36) was tested in healthy volunteers at low risk for HIV infection for their safety and immunogenicity. Both antigens were well tolerated. ALVAC-HIV (vCP205) induced low levels of neutralizing antibodies against HIV-1 MN in 33% of the volunteers. None of them had detectable neutralizing antibodies against a nonsyncytium-inducing HIV-1 clade B primary isolate (Bx08). After the fourth injection of vCP205, CTL activity was detected in 33% of the volunteers and was directed against Env, Gag, and Pol. This activity was mediated by both CD4+ and CD8+ lymphocytes. On the other hand, the CLTB-36 peptide was poorly immunogenic and induced no neutralizing antibodies or CTLs. Although the ALVAC-HIV (vCP205) and CLTB-36 prime-boost regimen was not optimal, further studies with ALVAC-HIV (vCP205) are warranted because of its clear induction of a cellular immune response and utility as a priming agent for other subunit antigens such as envelope glycoproteins, pseudoparticles, or new peptides.
authors.affiliation: CHU Cochin AP HP, Universite Paris, France.
authors.forename: D
authors.initials: D
authors.lastname: Salmon-Céron
authors.forename: J L
authors.initials: JL
authors.lastname: Excler
authors.forename: L
authors.initials: L
authors.lastname: Finkielsztejn
authors.forename: B
authors.initials: B
authors.lastname: Autran
authors.forename: J C
authors.initials: JC
authors.lastname: Gluckman
authors.forename: D
authors.initials: D
authors.lastname: Sicard
authors.forename: T J
authors.initials: TJ
authors.lastname: Matthews
authors.forename: B
authors.initials: B
authors.lastname: Meignier
authors.forename: C
authors.initials: C
authors.lastname: Valentin
authors.forename: R
authors.initials: R
authors.lastname: El Habib
authors.forename: C
authors.initials: C
authors.lastname: Blondeau
authors.forename: M
authors.initials: M
authors.lastname: Raux
authors.forename: C
authors.initials: C
authors.lastname: Moog
authors.forename: J
authors.initials: J
authors.lastname: Tartaglia
authors.forename: P
authors.initials: P
authors.lastname: Chong
authors.forename: M
authors.initials: M
authors.lastname: Klein
authors.forename: B
authors.initials: B
authors.lastname: Milcamps
authors.forename: F
authors.initials: F
authors.lastname: Heshmati
authors.forename: S
authors.initials: S
authors.lastname: Plotkin
mesh_terms: D016915:AIDS Vaccines / Q000009:adverse effects* / Q000276:immunology*; D000328:Adult; D000595:Amino Acid Sequence; D018150:Avipoxvirus / Q000235:genetics / Q000276:immunology*; D005260:Female; D005822:Genetic Vectors; D015483:HIV Antibodies / Q000096:biosynthesis* / Q000097:blood; D016655:HIV Core Protein p24 / Q000737:chemistry / Q000276:immunology; D015699:HIV Envelope Protein gp120 / Q000009:adverse effects / Q000737:chemistry / Q000276:immunology; D015497:HIV-1 / Q000276:immunology*; D006801:Humans; D007115:Immunization Schedule; D007117:Immunization, Secondary; D008213:Lymphocyte Activation; D008297:Male; D008875:Middle Aged; D008969:Molecular Sequence Data; D010455:Peptides / Q000138:chemical synthesis / Q000737:chemistry / Q000276:immunology; D013601:T-Lymphocytes / Q000276:immunology; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology; D014614:Vaccines, Synthetic / Q000009:adverse effects* / Q000276:immunology*
chemical_list: D016915:AIDS Vaccines; C000594377:ALVAC-HIV vCP205 vaccine; D015483:HIV Antibodies; D016655:HIV Core Protein p24; D015699:HIV Envelope Protein gp120; D010455:Peptides; D014614:Vaccines, Synthetic